Novartis India Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novartis India Ltd.
'Brands Don’t Die': Cipla Grabs Rights To Novartis’ Galvus In India
Novartis draws up perpetual license agreement with Cipla for its vildagliptin brand in India. Experts weigh in on some deal nuances and whether the DPP-4 inhibitor can deliver long-term value in an ultra-competitive segment.
BioAsia 2023: Leaders from Novartis, Apple Talk Innovation, Tech, Data Privacy
BioAsia 2023 was a melting pot of ideas with Novartis's CEO and a senior executive from Apple, among others, discussing a range of topics including the potential of novel therapies and platforms such as siRNA and radioligand and also where things were headed as the union of technology and biotech drives new insights into biology and promises to help reimagine healthcare.
Big Pharma Restructures Commercial Teams In India
More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.
Big Pharma Rescripts India Playbook
Big pharma appears to be resetting operations in India fueling some concerns of waning interest. In Vivo looks at what the realignment means or doesn’t.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.